Lyell CSO: New job is 'the missing piece' of his career; Orphazyme and Cortexyme and Sio, oh my: Your guide to the latest CEO changes
“I fully recognize that cell therapy is still all about the cells.”
In moving over to his second CSO job, Gary Lee says he hopes to grasp a “really critical” missing piece of the puzzle in cell therapy: T cell biology, something he hadn’t gotten a lot of exposure to. At Lyell Immunopharma, he will have an abundance of scientific knowledge and technologies at his disposal to figure out how to make the best cells possible.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
